WSNS Events
Save the Date!
2013 WSNS Annual Meeting
October 5, 2013
Seattle Conference Center
Eighth and Pike, Seattle, WA
Conference schedule and registration form coming soon!
WSNS News
FDA MedWatch – AED Potiga (Ezogabine) Linked To Retinal Abnormalities And Blue Skin Discoloration
FDA is warning the public that the anti-seizure medication Potiga (Ezogabine) can cause blue skin discoloration and eye abnormalities characterized by pigment changes in the retina. FDA does not currently know if these changes are reversible. FDA is working with the manufacturer to gather and evaluate all available information to better understand these events. FDA will update the public when more information is available. More (05/06/13)
FDA MedWatch - Valproate: Changed to Pregnancy Category X in Prevention of Migraine Headaches
ISSUE: FDA is advising health care professionals and women that the anti-seizure medication valproate sodium and related products, valproic acid and divalproex sodium, are contraindicated and should not be taken by pregnant women for the prevention of migraine headaches. Based on information from a recent study, there is evidence that these medications can cause decreased IQ scores in children whose mothers took them while pregnant. Stronger warnings about use during pregnancy will be added to the drug labels, and valproate's pregnancy category for migraine use will be changed from "D" (the potential benefit of the drug in pregnant women may be acceptable despite its potential risks) to "X" (the risk of use in pregnant women clearly outweighs any possible benefit of the drug). More (05/06/13)
What is a Neurologist?
